Timothy K. Andrews has served as our General Counsel and Secretary since November 2020. From 2016 through 2019 he served as General Counsel and Secretary for Sienna Biopharmaceuticals, Inc., a publicly traded, clinical-stage biotech company, where he was instrumental in acquiring the company’s core assets, planning and executing its IPO, and building the legal function and corporate governance systems. Mr. Andrews served as Senior Corporate Counsel and Assistant Secretary at Allergan, Inc. from 2011 through 2015, when the company was acquired by Actavis plc. At Allergan, Inc., he had legal responsibility for U.S. and international business development transactions, including acquisitions, licensing and partnerships, as well as corporate governance and securities law compliance. From 2006 to 2011, Mr. Andrews was a corporate attorney at Latham & Watkins LLP, where his practice focused on public company representation, mergers and acquisitions and corporate finance, serving clients in the life sciences sector, including Allergan. He was previously a Business Analyst at Deloitte Consulting. Mr. Andrews received a B.A. in Political Economy from the University of California, Berkeley and a J.D. from Loyola Law School, Los Angeles.
Ms. Brough has over fifteen years of experience in public and private accounting roles. She started her career as an auditor at Ernst & Young Assurance practice in San Diego, California. During the ten years as an auditor, Ms. Brough served many multinational public and private clients in life science, medical devices and technology industries. After Ernst & Young, Ms. Brough was Head of Finance at Human Longevity, Inc., a genomics-based company in San Diego, where she oversaw financial planning, accounting, treasury and procurement functions. Ms. Brough graduated from the San Diego State University with a Bachelor of Accounting degree.
Dr. Laurent joined Prometheus in September 2020 as Chief Technology Officer. Dr. Laurent most recently served as Chief Scientific Officer at Intrepida Bio, an immuno-oncology company focused on developing novel antibodies for the treatment of solid tumors. Prior to this position, Dr. Laurent spent twenty years designing and developing biopharmaceuticals at companies including Sanofi, Bayer HealthCare, Genentech, Pfizer, CovX (acquired by Pfizer in 2008) and Ambrx (acquired by a Chinese consortium in 2015). Dr. Laurent holds numerous patents in the field of biotherapeutics and has contributed to multiple antibody regulatory dossiers. Dr. Laurent holds a Ph.D. in Cell Biology from the University of Grenoble in France and is an alumnus of the École Normale Supérieure de Lyon.
Mr. Marshall was appointed as our Chief Financial Officer in August 2020. Prior to joining Prometheus, Mr. Marshall served as Executive Vice President, Chief Operating Officer and Chief Financial Officer of Conatus Pharmaceuticals (Nasdaq: CNAT) since 2017. Prior to Conatus, he served as Chief Financial Officer and Head of Corporate Development at Torque Therapeutics (now Repertoire Immune Medicines), a Flagship Pioneering company. Mr. Marshall also served as Managing Director in Healthcare Investment Banking at GCA Savvian Advisors, Managing Director, Co-founder, and Chief Financial Officer at Montgomery, Marshall Healthcare Partners, and Managing Director of Healthcare Investment Banking at Montgomery & Co. He began his career in investment banking at JP Morgan. Mr. Marshall holds an MBA from the University of Chicago – Booth School of Business, a Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco and an A.B. in Biology from Washington University in St. Louis.
Dr. Luo has served as Chief Medical Officer of Precision IBD, the predecessor of Prometheus Biosciences since August 2018. Prior to joining Prometheus Biosciences, Dr. Luo was Senior Vice President of Clinical Development for Gastroenterology at Progenity, and Vice President of Clinical Development at Ophthotech where she was responsible for the completion of two Phase 3 studies. Prior to Ophthotech, Dr. Luo was Executive Director at Bristol-Myers Squibb where she was responsible for Inflammatory Bowel Disease and led the Phase 3 program for Orencia (abatacept) and the Phase 2 program for eldelumab (anti-IP10 antibody) for ulcerative colitis and Crohn’s disease. Earlier in her career she was a Medical Director at Abbott Laboratories where she led the regulatory filing of Humira for rheumatoid arthritis in Japan and developed the clinical trial protocols for Humira in ulcerative colitis. Dr. Luo received her Bachelor of Science in Biochemistry and Doctor of Medicine degrees from Northwestern University, followed by a residency in internal medicine at Loyola University, and a fellowship in drug development at Abbott Laboratories (Abbvie).
Dr. Kruidenier has been active in pre-clinical GI research for over 20 years. Prior to joining Prometheus Biosciences, Laurens was VP of Discovery at Second Genome, where he was responsible for a portfolio of microbiome programs. Previously, Laurens held various positions at GlaxoSmithKline and at Takeda Pharmaceuticals, where he was Head of GI Immunology Research. Laurens received his PhD in Experimental Gastroenterology from Leiden University (The Netherlands), after which he continued his training in GI immunology as a post-doctoral fellow at the University of London. Over the years, his research has resulted in multiple publications in top scientific journals, including Gastroenterology, Nature and Nature Chemical Biology.
Mr. McKenna serves as President, CEO and member of the board of Prometheus Biosciences. Prior to joining Prometheus Biosciences, Mr. McKenna was President & CEO of Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies. He joined Salix in March 2016 as the Senior Vice President and General Manager, responsible for the company’s gastrointestinal franchise. During his tenure, Mr. McKenna successfully led the company through a series of key strategic acquisitions, the launch of a number of new products, and delivered strong operating performance, with revenue increasing from $1.2B to $2B. Prior to joining Salix, Mr. McKenna spent more than a decade with Bausch + Lomb, most recently as Senior Vice President/General Manager of its U.S. Vision Care business. Prior to Bausch + Lomb, Mark held several roles of increasing responsibility at Johnson & Johnson. Mark holds a B.S. in Marketing from Arizona State University, an MBA from Azusa Pacific University and is a Fellow with the University of Pennsylvania, Wharton School of Business.